Epidemiology & Health Data Insights (ISSN 3080-8111) is an international, open-access, peer-reviewed journal that advances epidemiology by integrating health data science. It fosters multidisciplinary collaboration to address global health challenges through evidence-based research, promoting equity and guiding healthcare policy. The journal covers a wide range of topics including disease surveillance, predictive modeling, public health interventions, and big data applications, with an editorial team of experts in epidemiology, biostatistics, and public health.

Call for Publications

We invite researchers, practitioners, and policymakers to submit manuscripts for publication in “Epidemiology & Health Data Insights”. The journal is committed to disseminating innovative and rigorous research that contributes to a deeper understanding of health trends, disease prevention, and healthcare delivery worldwide.

CURRENT ISSUE

Volume 2, Issue 3, 2026

(Ongoing)

Review Article

Appetite Regulation and Gastric Emptying of Semaglutide in Non-Diabetic Obese Adults: A Systematic Review

Uchechukwu Bethel Abioke, Isaac Baiden, Obiageri Ihuarulam Okeoma, Victoria Partey-Newman, Temitope Oluwatosin Adewale, Shadrach Oluchi Onyekezini, Ijeoma Linda Okwuowulu

Epidemiology and Health Data Insights, 2(3), 2026, ehdi035, https://doi.org/10.63946/ehdi/18334

ABSTRACT: Obesity is a chronic condition driven in part by disrupted appetite control and changes in gastrointestinal function, both of which contribute to excessive energy intake and progressive weight gain. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has been shown to produce meaningful weight loss in non-diabetic adults. Despite its growing clinical use, the physiological processes through which semaglutide influences appetite and gastric emptying have not been clearly brought together. This systematic review explored how semaglutide affects appetite regulation and gastric emptying, and how these effects relate to weight reduction.
A systematic search was conducted in PubMed, Google Scholar, and Dimensions for studies published between 2021 and 2026, in line with PRISMA 2020 guidelines. Study screening, data extraction, and risk-of-bias assessment were carried out using Covidence by two independent reviewers, with a third reviewer resolving any disagreements. Four studies met the inclusion criteria, consisting of randomized controlled trials and one retrospective cohort study.
Across randomized trials, semaglutide was consistently associated with greater improvements in appetite-related outcomes compared with placebo, including reductions in hunger scores and overall energy intake. Studies that assessed gastric physiology reported a notable delay in gastric emptying with semaglutide, particularly during the early stages of treatment. These physiological changes occurred alongside greater weight loss in semaglutide-treated participants compared with control groups. Longer-term findings suggested that appetite suppression was maintained over time and accompanied by clinically meaningful weight reduction, while observational data supported the effectiveness of semaglutide in routine clinical practice.
Overall, the findings suggest that the weight-reducing effects of semaglutide in non-diabetic adults with obesity are closely tied to its ability to suppress appetite and slow gastric emptying. These mechanisms appear to play a central role in its therapeutic benefits and help explain the sustained weight loss observed with treatment.